Alzor

Quick links to important sections

Alzor

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alzor

Property Description
Active ingredient Olmesartan medoxomil
Form Film-coated tablet
Pharmacological class Angiotensin II Receptor Antagonist (ARB)
Common purpose Blood pressure regulation
Origin Synthetic compound

What Type of Medicine is Alzor and What is it Made Of?

Alzor is a prescription-only medicine containing the active substance Olmesartan medoxomil, which is classified as an Antihypertensive agent. The drug entity is a synthetic compound, chemically synthesized and not derived from natural sources, designed for the long-term, systemic management of cardiovascular conditions. This medication is manufactured as an oral formulation provided in the form of a film-coated tablet, suitable for being swallowed by mouth. The primary component, Olmesartan medoxomil, is a single active ingredient product (monotherapy), which the body quickly converts into the active molecule, Olmesartan, to execute its therapeutic action.


Classification and General Purpose: Why is Alzor Prescribed?

Alzor is classified as an Angiotensin II Receptor Antagonist (ARB), often referred to as a Sartan, a pharmacological group that targets the Renin-Angiotensin-Aldosterone System (RAAS). The general therapeutic purpose of this medication is the sustained regulation of blood pressure within a healthy range, an effect for managing chronic hypertension. This class of drug works by selectively interfering with the body's RAAS, a crucial regulatory pathway that controls blood vessel tone. By blocking the action of Angiotensin II—a powerful natural vasoconstrictor—the medication promotes vasodilation (vessel relaxation). The overall objective is to lessen the workload on the heart, supporting the foundational goal of minimizing cardiovascular risk factors through controlled vascular modulation.

What side effects are possible with Alzor?

Possible Side Effects and Safety Information for Alzor

This section addresses the official safety profile and known adverse reactions associated with the name Alzor as documented by major governmental drug regulatory authorities, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), Health Canada, and the National Institutes of Health (NIH).

Absence of Official Regulatory Safety Profile

As of the current date, a product named Alzor does not appear to be an approved pharmaceutical drug with publicly released official prescribing information or a summary of product characteristics (SmPC) from major, authoritative government regulatory bodies. Consequently, no officially documented list of side effects, frequency classifications (e.g., 'very common,' 'rare'), or system-organ-class groupings for adverse reactions can be provided based on governmental regulatory sources.

Authoritative drug safety information relies strictly on data reviewed and formalized by regulatory agencies. Without a verified regulatory status, an official safety profile cannot be established, meaning there are no publicly accessible, government-confirmed serious adverse reactions, population-specific safety considerations, or official safety restrictions for this name. Any information regarding possible side effects or safety limitations would need to be sourced from the formal regulatory label, which is not available for this substance name.

Safety Monitoring

When a medication is approved, governmental agencies provide a comprehensive safety framework, including specific details on clinically significant adverse reactions and necessary safety monitoring. The lack of an official regulatory designation means this fundamental public health information is unavailable. Individuals should not use any substance without a clear, verified safety profile approved by a competent government authority.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Olmesartan medoxomil (Alzor) is primarily characterized by clinical signs of an exaggerated therapeutic effect. Immediate medical attention must be sought for any suspected overdose [NIH MedlinePlus].

The most likely and principal manifestation documented in regulatory sources is hypotension (low blood pressure), which may cause profound dizziness or fainting. Other regulator-documented clinical signs include disturbances in heart rhythm, presenting as either tachycardia (increased heart rate) or, less commonly, bradycardia (decreased heart rate).

Severe Outcomes and Emergency Action

Severe overdosage risks include cardiovascular shock and acute renal failure secondary to profound and sustained hypotension. Altered levels of consciousness, such as stupor, is also a potential severe outcome in extreme cases. In situations involving severe hypotension, fainting, or altered consciousness, it is mandatory to contact emergency services immediately.

Management and Supportive Procedures

According to regulatory guidelines, no specific antidote is known for Olmesartan, and the substance is not expected to be removed by dialysis. Management of an overdose is strictly symptomatic and supportive. Officially described procedures focus on correcting hypotension and maintaining vital function through intravenous volume expansion (e.g., normal saline infusion) and close monitoring of vital signs, including heart rhythm and renal function.

Therapeutic Uses of Alzor

What Alzor Treats: Main Uses and Benefits

The primary therapeutic role of Alzor is relevant in the management of high blood pressure (hypertension). Alzor is commonly used to help manage the category of conditions presenting with high blood pressure in adults and children. It is applied to help manage symptoms related to heightened physiological activity in the circulatory system.

This is relevant in clinical scenarios where consistent support is needed for managing conditions presenting with increased systemic burden and potential for organ-specific functional stress. The medication may be part of symptomatic management for hypertension, which is a key step in reducing the associated risks.

Alzor contributes to long-term patient-oriented benefits. These benefits may help patients cope more steadily with the condition, which involves systemic or localized discomfort and symptoms that interfere with daily functioning. The medication may assist with managing the overall systemic burden associated with high blood pressure.

“This medication contributes to improved comfort during periods of increased systemic burden by supporting the reduction of high pressure readings.”

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Alzor — Official Regulatory Information

Eligibility for using Alzor (Olmesartan medoxomil) is determined by definitive, non-advisory rules established in government regulatory documents.


Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Adults with hypertension. Children and adolescents aged 6 years to less than 18 years with hypertension.
Populations for whom use is not recommended Use during breastfeeding/lactation. Use in children under 6 years of age. Patients with severe hepatic impairment or severe renal impairment (CrCl < 20 mL/min).
Populations for whom use is contraindicated Patients with known hypersensitivity to the drug. Patients in the second and third trimesters of pregnancy. Patients with diabetes mellitus or renal impairment receiving Aliskiren.

Resulting Eligibility Structure

Official eligibility statements:

  • Adults and children ge 6 years are the officially approved populations for use.
  • The medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury.
  • Severe organ impairment (hepatic or renal) is a condition where use is officially not recommended due to limited clinical experience.
  • Use is contraindicated if a patient with diabetes or renal impairment is concurrently receiving Aliskiren.
  • Patients with volume or salt depletion must be managed under close medical supervision at treatment initiation.

Connection to the overall eligibility profile:

Regulatory documents define eligibility by establishing absolute contraindications that prohibit use under specific conditions, primarily fetal risk. They also classify populations based on age (minimum 6 years established) and organ function, using the not recommended status when safety and efficacy data are officially limited or absent.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Alzor (Olmesartan medoxomil) is structured around several critical interaction patterns documented in government sources, primarily concerning additive systemic effects and modifications to drug exposure.


Interaction-Related Restrictions

Interaction Classification Interacting Substance/Class Official Constraint/Outcome
Formal Contraindication Aliskiren Co-administration is formally prohibited in patients with diabetes mellitus or moderate to severe renal impairment due to the heightened risk of severe hypotension and hyperkalemia.
Timing Requirement Colesevelam hydrochloride This substance reduces Olmesartan's systemic exposure (AUC and Cmax), a pharmacokinetic interaction. To mitigate this effect, Olmesartan must be administered at least 4 hours prior to Colesevelam.

Pharmacodynamic and Substance Interactions

Co-administration with agents that increase serum potassium, such as Potassium-sparing diuretics (e.g., Spironolactone) and potassium supplements, carries an officially documented additive pharmacodynamic risk of hyperkalemia.

Concurrently using Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may lead to a reduction in the antihypertensive efficacy of Alzor and an increased risk of worsening renal function. The co-administration of Lithium may result in an increase in serum lithium concentrations, raising the risk of toxicity. Regulatory summaries also document that consumption of alcohol may potentiate the risk of orthostatic hypotension. Olmesartan is noted as being minimally metabolized by the CYP450 enzyme system; therefore, specific CYP-mediated drug interactions are not clinically documented.

Mechanism of Action

How Alzor Works: Mechanism of Action

Alzor exerts its physiological effects through pharmacodynamic interaction with specific molecular targets across key mechanistic domains. The drug initiates a focused signaling cascade by modulating molecular steps that govern cellular responsiveness.


Modulating Receptor-Mediated Signaling

This domain involves Alzor's interaction with specific cell-surface receptors, where it functions as either an agonist or antagonist of endogenous mediator binding. This action modifies the subsequent intracellular signaling sequences, resulting in the specific modification of downstream pathways and promoting pathway-level adjustments toward baseline activity.


Engaging Feedback Regulation in Key Pathways

Alzor selectively influences complex signaling cascades where multiple layers of activation occur. By modifying early molecular steps, the drug influences intrinsic feedback regulation within the pathway, which effectively modulates the magnitude and duration of downstream physiological effects. This leads to measurable alterations in systemic physiological parameters.

Dosage and Administration Information

How to Use Alzor

The general principles of using Alzor (Olmesartan medoxomil) are defined by specific dosing schedules and administration guidelines. This medicine is for oral administration as a film-coated tablet, although instructions for preparing an extemporaneous oral suspension are available for patients unable to swallow the tablet.

Standard Dosing Regimens

The therapy typically begins with an adult starting dose of 10 mg or 20 mg once daily. The drug is taken once daily (QD), and administering the same total dose divided over two times offers no advantage. Administration may occur with or without food, but it is recommended to take the dose at approximately the same time each day to maintain a consistent routine.

Dose Adjustment and Duration

The dosage may be increased if the blood pressure is not adequately controlled after an initial period, typically two weeks of therapy, up to a maximum recommended daily dose of 40 mg. The maximal therapeutic effect is generally observed after about eight weeks of continuous use. If a dose is missed, the next dose is taken at the regularly scheduled time, rather than taking two doses together.

Population-Specific Use

Dosage is modified for certain populations. For pediatric patients aged 6 to less than 18 years, the dosage is determined by body weight, ranging from 10 mg to 40 mg once daily. For adults with moderate renal or hepatic impairment, the maximum daily dose should not exceed 20 mg, defining a usage limit for these patient groups.

Recent Clinical Evidence

Alzor (Olmesartan): Clinical Evidence Summary

Alzor is a brand name for the active ingredient Olmesartan medoxomil, which belongs to the class of medications known as Angiotensin II Receptor Blockers (ARBs). Clinical studies, including randomized controlled trials (RCTs), have primarily focused on evaluating its effect on blood pressure in patients diagnosed with essential hypertension.


Efficacy in Blood Pressure Reduction

Research indicates that Olmesartan provides a dose-dependent reduction in both systolic and diastolic blood pressure. A key finding across multiple trials is that the blood pressure-lowering effect is typically sustained over the full 24-hour dosing interval, which supports once-daily administration. Significant reductions in blood pressure have been observed as early as two weeks after initiating therapy, with maximal effects usually achieved by eight weeks.

In comparative studies, Olmesartan has demonstrated similar or greater reductions in diastolic blood pressure compared to some other commonly prescribed ARBs (such as Losartan, Irbesartan, and Valsartan) and other classes of antihypertensive agents (such as Atenolol and Amlodipine), particularly at recommended starting doses. These comparative observations relate specifically to blood pressure measurements, not necessarily to long-term cardiovascular outcomes.


Combination Therapy Studies

Alzor is also available in combination with other active ingredients, such as a thiazide diuretic (e.g., Hydrochlorothiazide) or a calcium channel blocker (e.g., Amlodipine). Studies evaluating these fixed-dose combinations have shown that adding a second or third agent can lead to further, significant reductions in blood pressure for patients whose hypertension is not adequately controlled with Olmesartan monotherapy alone. For instance, the combination of Olmesartan and Amlodipine has been associated with achieving blood pressure targets in a substantial proportion of patients.

Research continues to investigate the long-term impact of Olmesartan and its combinations on complex clinical outcomes, such as the reduction of cardiovascular events like stroke or myocardial infarction, although the primary established benefit is the consistent lowering of elevated blood pressure.

Key Studies & References

  1. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study (Primary combination RCT)

Frequently Asked Questions (FAQ)

Common questions about Alzor (FAQ)

Q: Is Alzor used for more than one health condition?

Alzor, which contains Olmesartan, is officially indicated by regulatory authorities for the treatment of high blood pressure (hypertension). Its primary purpose is to help regulate blood pressure within a healthy range. Studies involving Olmesartan in combination with other medicines have investigated additional cardiovascular outcomes.

Q: Are there any common side effects people report when first starting Alzor?

Official drug labels state that common adverse reactions include mild effects such as dizziness and headache. Patients may also report feeling generally fatigued or experiencing symptoms similar to a mild flu. These are listed in the official Adverse Reactions sections of the prescribing information.

Q: Is it normal to feel a certain way when taking Alzor?

When starting treatment, some individuals may feel lightheaded or dizzy. Official information indicates this feeling can be associated with the blood pressure-lowering effect of the medication. If these feelings are severe or concerning, seeking guidance from a healthcare professional is appropriate.

Q: What kind of side effects are generally considered mild with Alzor?

According to official product information, adverse reactions that are generally common and considered mild include headache, dizziness, back pain, and minor upper respiratory symptoms. Your healthcare provider has access to the full official list of documented effects.

Q: Is Alzor known to cause weight changes?

Official regulatory documents describe a rare but serious condition called Sprue-like enteropathy which can occur with this class of drug. This condition is characterized by severe, chronic diarrhea and may lead to substantial weight loss. The presence of these signs is noted in regulatory documents as requiring prompt medical review.

Q: Can Alzor affect sleep patterns?

Sleep disorders are generally not listed as a common or frequent adverse reaction in the official product information. Sleep issues, if experienced, are typically discussed with a healthcare professional.

Q: Does Alzor require any specific lifestyle changes?

Official information indicates that complementary management, such as improvements to diet and exercise, is often discussed with medication for high blood pressure. Effective treatment for high blood pressure is generally considered comprehensive.

Q: Are there any vitamins or supplements that should be avoided with Alzor?

Regulatory warnings specifically caution against the use of potassium supplements and salt substitutes that contain potassium. This is because co-administration carries an increased risk of high potassium levels (hyperkalemia) in the blood.

Q: Is Alzor considered safe for older adults?

Studies reviewed by regulatory bodies have indicated that Alzor can be used by older adults. Clinical trials compared safety and effectiveness in patients both under and over 65 years of age. Generally, no specific dose adjustment is required based on age alone.

Q: What is the difference between Alzor and a generic version of the medicine?

Alzor is the brand name for the active ingredient olmesartan medoxomil. Generic versions contain the identical active ingredient. According to regulatory standards, generic medicines must meet the same strict requirements for quality and must be demonstrated to be bioequivalent to the brand-name product.

Q: Is Alzor a narcotic or habit-forming drug?

No, Alzor (olmesartan medoxomil) is not classified as a controlled substance by regulatory agencies. This medication is not a narcotic and is not considered to be habit-forming.

Q: What should I know about the long-term use of Alzor?

The management of high blood pressure is often a long-term commitment. Official studies have shown that the blood pressure-lowering effect of Olmesartan is sustained with continued, consistent use over time, and no diminished effectiveness has been reported.

Q: What do research studies suggest about how often Alzor helps people?

Clinical trial data indicates that for many patients whose blood pressure is not adequately controlled on a lower dose, increasing the dose of Olmesartan provides additional and significant blood pressure reduction. The overall goal of therapy is to help patients reach their specific, individualized blood pressure targets.

Q: Are there any major studies comparing Alzor to a placebo?

Yes, regulatory approval was based on several placebo-controlled studies of 6 to 12 weeks duration. These trials demonstrated that the drug achieved a reliable, dose-related reduction in blood pressure compared to treatment with an inactive placebo.

Q: Is Alzor the same kind of medicine as [similar sounding/common drug name]?

Alzor belongs to a specific pharmacological group known as Angiotensin II Receptor Blockers (ARBs). This class works by blocking the AT1 receptor. This distinguishes its mechanism of action from other classes of blood pressure medications, like ACE inhibitors or beta-blockers.

Q: Can Alzor affect my ability to drive or operate machinery?

Because Olmesartan may cause side effects like dizziness or tiredness, official guidance advises caution. Official guidance notes that individuals should observe their reaction to the medication, particularly upon initiation, before driving or engaging in complex tasks.

Q: Where can I find the official drug information sheet for Alzor?

The official documentation, such as the Prescribing Information or the Summary of Product Characteristics (SmPC), for the active ingredient (Olmesartan medoxomil) is generally available online. You can typically find this information on the websites of government drug regulatory agencies like the FDA (DailyMed) or the EMA.

Q: Is Alzor known to cause any skin-related issues?

Regulatory documents include reports of serious, rare skin reactions such as angioedema, which involves swelling of the face, lips, or throat. The occurrence of severe swelling or unexpected skin issues is an official warning that indicates the need for prompt medical evaluation.

Q: What are the general rules for stopping Alzor treatment?

Official studies have not reported a sudden increase in blood pressure, known as rebound hypertension, following abrupt withdrawal of the drug after long-term use. Discontinuation or changes to the treatment plan are managed by a healthcare provider.

Q: Can Alzor make me feel tired or lethargic?

Official prescribing information includes reports of feelings such as fatigue and unusual weakness as potential adverse reactions that have been reported during use of the medication.

Q: What if I experience side effects that aren't listed in the official documents?

Official patient instructions define the process for reporting suspected adverse reactions to a healthcare provider or directly to the government’s drug monitoring authority (e.g., FDA’s MedWatch program).

Q: Are there any known issues with taking Alzor before surgery?

Official warnings note that surgical procedures requiring anesthesia may increase the risk of a significant drop in blood pressure (hypotension) in patients taking medications that affect the renin-angiotensin system, like Olmesartan.

Q: Can Alzor be taken by people with diabetes?

Alzor is officially contraindicated (must not be used) in patients diagnosed with diabetes mellitus who are concurrently taking any medication that contains the active ingredient aliskiren.

Q: Do I need to have regular blood tests while taking Alzor?

Official guidance documents indicate that periodic monitoring may be necessary, particularly for certain patient groups. Checks for serum creatinine (kidney function) and serum electrolytes, such as potassium levels, are noted as part of the overall management plan.

Q: Does Alzor have a rebound effect if stopped suddenly?

Clinical studies have indicated that there is no reported risk of a sudden, sharp rise in blood pressure, known as rebound hypertension, if the treatment is abruptly discontinued after long-term use.

Q: What is the mechanism mentioned in the 'How it works' section in plain language?

In simple terms, Alzor works by blocking a key receptor in the body. It stops a natural hormone called Angiotensin II from tightening blood vessels. This results in the blood vessels relaxing and widening, which lowers blood pressure.

Q: What is the typical shelf-life or expiration concern for Alzor?

Official regulatory approval documents specify the exact shelf-life of the product, which can vary depending on the packaging. Storage conditions, typically controlled room temperature, are defined in the regulatory documentation to ensure the stability and effectiveness of the medication until its specified expiration date.

How should Alzor be stored and disposed of?

How to Store and Dispose of Alzor

Alzor (amlodipine/olmesartan medoxomil) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the container tightly closed and protect the tablets from excessive heat, moisture, and light.
Child Safety Store the medicine out of the sight and reach of children.

Disposal

Unused or expired Alzor should be disposed of properly. Consult a pharmacist or healthcare professional for information regarding local drug take-back programs or collection sites. Do not flush the tablets down a toilet or pour them into a drain unless specifically instructed otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alzor found in:

A-Z Index: